DK1037917T3 - Rekombinante nodavirus sammensætninger og fremgangsmåder - Google Patents
Rekombinante nodavirus sammensætninger og fremgangsmåderInfo
- Publication number
- DK1037917T3 DK1037917T3 DK98961962T DK98961962T DK1037917T3 DK 1037917 T3 DK1037917 T3 DK 1037917T3 DK 98961962 T DK98961962 T DK 98961962T DK 98961962 T DK98961962 T DK 98961962T DK 1037917 T3 DK1037917 T3 DK 1037917T3
- Authority
- DK
- Denmark
- Prior art keywords
- nodavirus
- compositions
- methods
- recombinant
- particles
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 238000001476 gene delivery Methods 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/30011—Nodaviridae
- C12N2770/30022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/882—Assembling of separate components, e.g. by attaching
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/92—Detection of biochemical
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/986,659 US6171591B1 (en) | 1997-12-08 | 1997-12-08 | Recombinant nodavirus compositions and methods |
| PCT/US1998/025922 WO1999029723A1 (fr) | 1997-12-08 | 1998-12-07 | Compositions de nodavirus recombines et methodes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1037917T3 true DK1037917T3 (da) | 2007-10-08 |
Family
ID=25532635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98961962T DK1037917T3 (da) | 1997-12-08 | 1998-12-07 | Rekombinante nodavirus sammensætninger og fremgangsmåder |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6171591B1 (fr) |
| EP (1) | EP1037917B1 (fr) |
| JP (1) | JP4503172B2 (fr) |
| AT (1) | ATE366743T1 (fr) |
| AU (1) | AU755201B2 (fr) |
| BR (1) | BR9813416A (fr) |
| CA (1) | CA2313704C (fr) |
| CY (1) | CY1106842T1 (fr) |
| DE (1) | DE69838073T2 (fr) |
| DK (1) | DK1037917T3 (fr) |
| ES (1) | ES2288769T3 (fr) |
| IL (2) | IL136634A0 (fr) |
| PT (1) | PT1037917E (fr) |
| WO (1) | WO1999029723A1 (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1637166A3 (fr) * | 1998-10-21 | 2006-04-12 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Particules assimilées à des virus pour l'induction d'auto-anticorps |
| AU770802B2 (en) | 1998-10-21 | 2004-03-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Virus-like particles for the induction of autoantibodies |
| DE60034947T2 (de) * | 1999-06-30 | 2008-01-24 | Evotec Ag | Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung |
| US20040014033A1 (en) | 1999-06-30 | 2004-01-22 | Evotec Biosystems Ag, A Corporation Of Germany | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
| US7476517B2 (en) | 1999-06-30 | 2009-01-13 | Evotec Ag | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
| IL159671A0 (en) * | 2001-07-02 | 2004-06-01 | Bioincept Inc | New assays for preimplantation factor and preimplantation factor peptides |
| US8222211B2 (en) * | 2001-07-02 | 2012-07-17 | Bioincept, Llc | Methods of administering PIF agonist peptides and uses thereof |
| ATE447967T1 (de) | 2001-09-14 | 2009-11-15 | Cytos Biotechnology Ag | Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung |
| EP1318195A1 (fr) * | 2001-12-10 | 2003-06-11 | CatchMabs B.V. | Une structure pour la présentation des séquences de peptides désirées |
| US9045727B2 (en) | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| WO2004042001A2 (fr) * | 2002-05-17 | 2004-05-21 | Emory University | Particules pseudovirales, procede de fabrication et compositions immunogeniques |
| JP5022028B2 (ja) | 2003-03-26 | 2012-09-12 | サイトス・バイオテクノロジー・アクチェンゲゼルシャフト | メラン−aペプチドアナログ−ウイルス様粒子コンジュゲート |
| US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
| US7723290B2 (en) | 2004-10-22 | 2010-05-25 | Bioincept, Llc | Compositions and methods for modulating the immune system |
| JP2005272340A (ja) * | 2004-03-24 | 2005-10-06 | Japan Science & Technology Agency | ノダウイルスの感染予防法および治療法 |
| EP1885394A4 (fr) * | 2005-06-01 | 2009-10-21 | Dow Global Technologies Inc | Production de particules multivalentes semblables à des virus |
| ES2310062B1 (es) | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
| EP1973608A1 (fr) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Particules emballees avec des acides nucleiques immunostimulateurs pour le traitement de l hypersensibilite |
| EP1835031A1 (fr) | 2006-03-14 | 2007-09-19 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Utilisation d'un virus de la vaccine Ankara modifiée (MVA) recombinant pour le traitement de l'hypersensibilité de type I chez un animal vivant comprenant les humains |
| NZ573622A (en) | 2006-06-12 | 2011-12-22 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
| CA2671873C (fr) | 2006-12-12 | 2018-10-09 | Brian Stephen Sproat | Oligonucleotides contenant des concentrations elevees en monomeres de guanine |
| US7998487B2 (en) * | 2007-02-16 | 2011-08-16 | The Salk Institute For Biological Studies | Antitoxin and vaccine platform based on nodavirus VLPs |
| US20090093019A1 (en) * | 2007-04-27 | 2009-04-09 | Phelps Jamie P | Production and in vivo assembly of soluble recombinant icosahedral virus-like particles |
| WO2009055491A2 (fr) * | 2007-10-22 | 2009-04-30 | University Of Rochester | Vaccin contre le virus syncytial respiratoire basé sur des capsomères ou des particules chimériques semblables au virus du papillomavirus |
| EP2680872B1 (fr) | 2011-03-02 | 2018-08-15 | BioIncept LLC | Compositions et procédés pour traiter des lésions intracellulaires |
| ES2717876T3 (es) | 2011-12-12 | 2019-06-26 | Childrens Hospital Philadelphia | Sistema de producción de un vector lentiviral a gran escala comercial y vectores así producidos |
| EP3184639B1 (fr) * | 2014-08-21 | 2019-06-12 | Chung-Ang University Industry-Academy Cooperation Foundation | Ensemble de cassette d'insertion multiple de gènes à base de rdna nts et souche de levure recombinée de qualité gras |
| CA2996874A1 (fr) | 2015-08-28 | 2017-03-09 | Bioincept, Llc | Compositions et methodes pour le traitement d'une lesion neurologique |
| EP3341739A4 (fr) | 2015-08-28 | 2019-07-10 | BioIncept LLC | Peptides mutants et procédés de traitement de sujets les employant |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
| US4873192A (en) * | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| EP0698666B1 (fr) * | 1994-06-21 | 2006-04-26 | Sumitomo Electric Industries, Limited | Epimorphine modifiée |
| AT402898B (de) | 1994-08-08 | 1997-09-25 | Int Centre Genetic Eng & Bio | Molekulares präsentiersystem |
| US5869287A (en) * | 1996-07-12 | 1999-02-09 | Wisconsin Alumni Research Foundation | Method of producing particles containing nucleic acid sequences in yeast |
-
1997
- 1997-12-08 US US08/986,659 patent/US6171591B1/en not_active Expired - Lifetime
-
1998
- 1998-12-07 PT PT98961962T patent/PT1037917E/pt unknown
- 1998-12-07 AU AU17146/99A patent/AU755201B2/en not_active Ceased
- 1998-12-07 IL IL13663498A patent/IL136634A0/xx active IP Right Grant
- 1998-12-07 DK DK98961962T patent/DK1037917T3/da active
- 1998-12-07 JP JP2000524314A patent/JP4503172B2/ja not_active Expired - Fee Related
- 1998-12-07 BR BR9813416-7A patent/BR9813416A/pt not_active Application Discontinuation
- 1998-12-07 AT AT98961962T patent/ATE366743T1/de active
- 1998-12-07 EP EP98961962A patent/EP1037917B1/fr not_active Expired - Lifetime
- 1998-12-07 CA CA002313704A patent/CA2313704C/fr not_active Expired - Fee Related
- 1998-12-07 DE DE69838073T patent/DE69838073T2/de not_active Expired - Lifetime
- 1998-12-07 ES ES98961962T patent/ES2288769T3/es not_active Expired - Lifetime
- 1998-12-07 WO PCT/US1998/025922 patent/WO1999029723A1/fr not_active Ceased
-
2000
- 2000-06-07 IL IL136634A patent/IL136634A/en not_active IP Right Cessation
-
2007
- 2007-09-04 CY CY20071101142T patent/CY1106842T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1037917E (pt) | 2007-09-19 |
| IL136634A (en) | 2007-09-20 |
| EP1037917B1 (fr) | 2007-07-11 |
| CA2313704A1 (fr) | 1999-06-17 |
| DE69838073T2 (de) | 2008-03-20 |
| WO1999029723A1 (fr) | 1999-06-17 |
| ES2288769T3 (es) | 2008-01-16 |
| US6171591B1 (en) | 2001-01-09 |
| ATE366743T1 (de) | 2007-08-15 |
| BR9813416A (pt) | 2001-10-16 |
| JP4503172B2 (ja) | 2010-07-14 |
| CY1106842T1 (el) | 2012-05-23 |
| EP1037917A1 (fr) | 2000-09-27 |
| AU1714699A (en) | 1999-06-28 |
| AU755201B2 (en) | 2002-12-05 |
| EP1037917A4 (fr) | 2003-02-26 |
| DE69838073D1 (de) | 2007-08-23 |
| CA2313704C (fr) | 2009-04-07 |
| JP2001525422A (ja) | 2001-12-11 |
| IL136634A0 (en) | 2001-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1037917T3 (da) | Rekombinante nodavirus sammensætninger og fremgangsmåder | |
| ATE327259T1 (de) | Immunantwort gegen hpv antigene hervorgerufen von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einem expressionsvektor fähig zur expression dieser proteine | |
| HUP0500345A2 (hu) | Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására | |
| ATE500323T1 (de) | Subtilisin-variante | |
| DE60041243D1 (de) | Gebrauchsverfaheren eines neuen lysyloxidase-verwandten proteins | |
| DE3682893D1 (de) | Charakteristische polypeptide und antikoerper vom papillomavirus, diagnostische verfahren und dieselben verwendende impfungen. | |
| NZ500540A (en) | Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae | |
| DE60131413D1 (de) | Verfahren zum auffinden von peptiden zur verwendung in der immuntherapie | |
| DE60144021D1 (de) | Für zellzyklusproteine kodierende nukleinsäure und deren verwendung | |
| MY110899A (en) | Dengue virus | |
| WO2001057219A3 (fr) | Cytokines mammaliennes, leurs recepteurs, reactifs et procedes correspondants | |
| DK0625157T3 (da) | Blodplade-GPIIIaP1A1- og -P1A2-epitoper og fremstilling og anvendelse deraf | |
| AP2368A (en) | Novel expression vectors and uses thereof. | |
| ATE124420T1 (de) | Impfstoffe und testsätze für haemophilus influenzae. | |
| ATE470716T1 (de) | 18480 humane proteinkinasemoleküle und ihre verwendungen | |
| DE60124910D1 (de) | Menschliche twik-8 moleküle und ihre verwendung | |
| DK1328621T3 (da) | 13245, en ny human proteinkinase af den myotoniske dystrofitype og anvendelser deraf | |
| WO2002051992A3 (fr) | 21163, nouvelle propyle oligopeptidase humaine et utilisations correspondantes | |
| DE60136832D1 (de) | Atcr-1, eine humane acyltransferase und verwendungen davon | |
| AU2001281943A1 (en) | The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof | |
| ATE435285T1 (de) | 14189, eine humane kinase und deren verwendungen | |
| AR003968A1 (es) | Peptidos del virus de la arteritis equina, anticuerpos, una composicion para una vacuna, adn y arn recombinante, un plasmido, una celula, antisueros yanticuerpos, un metodo para analizar la presencia o cantidad de anticuerpos y del virus, y un equipo de ensayo |